DE69406423T2 - Methode zum überbringen von agenzien an zielzellen - Google Patents
Methode zum überbringen von agenzien an zielzellenInfo
- Publication number
- DE69406423T2 DE69406423T2 DE69406423T DE69406423T DE69406423T2 DE 69406423 T2 DE69406423 T2 DE 69406423T2 DE 69406423 T DE69406423 T DE 69406423T DE 69406423 T DE69406423 T DE 69406423T DE 69406423 T2 DE69406423 T2 DE 69406423T2
- Authority
- DE
- Germany
- Prior art keywords
- target cells
- delivering agents
- agents
- delivering
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/002,324 US5861156A (en) | 1993-01-08 | 1993-01-08 | Methods of delivering agents to target cells |
PCT/US1994/000261 WO1994015642A1 (en) | 1993-01-08 | 1994-01-07 | Methods of delivering agents to target cells |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69406423D1 DE69406423D1 (de) | 1997-11-27 |
DE69406423T2 true DE69406423T2 (de) | 1998-09-03 |
Family
ID=21700250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69406423T Expired - Fee Related DE69406423T2 (de) | 1993-01-08 | 1994-01-07 | Methode zum überbringen von agenzien an zielzellen |
Country Status (9)
Country | Link |
---|---|
US (1) | US5861156A (de) |
EP (1) | EP0679093B1 (de) |
JP (1) | JPH08505623A (de) |
AT (1) | ATE159429T1 (de) |
AU (1) | AU673581B2 (de) |
CA (1) | CA2153568A1 (de) |
DE (1) | DE69406423T2 (de) |
ES (1) | ES2113088T3 (de) |
WO (1) | WO1994015642A1 (de) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6696251B1 (en) * | 1996-05-31 | 2004-02-24 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
WO1998008875A1 (de) * | 1996-08-28 | 1998-03-05 | Viva Diagnostika Diagnostische Produkte Gmbh | Kombinationspräparationen und ihre verwendung in der immundiagnostik und immuntherapie |
FR2766826B1 (fr) * | 1997-08-04 | 2001-05-18 | Pasteur Institut | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules |
CN1276830A (zh) | 1997-09-02 | 2000-12-13 | 住友制药株式会社 | 抗乙型肝炎病毒核心蛋白的单链抗体及其基因和含有它们的乙型肝炎治疗药物 |
US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
BRPI9909220B1 (pt) * | 1998-02-20 | 2018-09-18 | Genentech Inc | hibridoma, anticorpo monoclonal, anticorpo humanizado, anticorpo quimérico, anticorpo desimunizado ou fragmento de tais anticorpos |
US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
AU755706B2 (en) * | 1998-03-20 | 2002-12-19 | Genzyme Corporation | Methods to provoke anti-cancer immune responses |
EP1247095B1 (de) * | 1999-12-06 | 2008-10-15 | Board Of Trustees Of The University Of Illinois | Hochaffine t-zellrezeptorproteine und verfahren |
WO2001070818A1 (en) * | 2000-03-23 | 2001-09-27 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
WO2002046400A2 (en) * | 2000-12-08 | 2002-06-13 | The Board Of Trustees Of The University Of Illinois | Mutated class ii major histocompatibility proteins |
US7445802B2 (en) * | 2000-12-26 | 2008-11-04 | Yeda Research And Development Co. Ltd | Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases |
KR20050036875A (ko) * | 2001-10-15 | 2005-04-20 | 이뮤노메딕스, 인코오포레이티드 | 직접 표적형의 결합 단백질 |
US7858367B2 (en) * | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
US20040072728A1 (en) * | 2002-06-26 | 2004-04-15 | Fawwaz Rashid A. | Use of streptavidin to inhibit transplant rejection |
US20060034767A1 (en) * | 2002-07-05 | 2006-02-16 | Roger Williams Medical Center | Targeting and tracking of cells to specific organs and tissues in vivo |
US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
BR0315942A (pt) * | 2002-11-27 | 2005-10-04 | Dmi Biosciences Inc | Tratamento de doenças e condições mediadas pelo aumento de fosforilação |
GB2408507B (en) * | 2003-10-06 | 2005-12-14 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof for specific targeting |
WO2005116071A2 (en) * | 2004-05-28 | 2005-12-08 | University Of Massachusetts | Snares for pathogenic or infectious agents and uses related thereto |
US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
KR20180002911A (ko) * | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
CA2646329C (en) * | 2006-03-20 | 2018-07-03 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
GB2442048B (en) * | 2006-07-25 | 2009-09-30 | Proimmune Ltd | Biotinylated MHC complexes and their uses |
NZ609813A (en) * | 2006-11-02 | 2015-01-30 | Genentech Inc | Humanized anti-factor d antibodies and uses thereof |
JP6126773B2 (ja) * | 2007-09-04 | 2017-05-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原(psca)抗体 |
US20100291113A1 (en) * | 2007-10-03 | 2010-11-18 | Cornell University | Treatment of Proliferative Disorders Using Antibodies to PSMA |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
US20100016782A1 (en) * | 2008-07-16 | 2010-01-21 | John Erich Oblong | Method of Regulating Hair Growth |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
US10517969B2 (en) * | 2009-02-17 | 2019-12-31 | Cornell University | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
RU2673908C2 (ru) | 2009-12-02 | 2018-12-03 | Имэджинэб, Инк. | Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения |
CN103370311A (zh) * | 2010-10-22 | 2013-10-23 | 斯特拉斯堡大学 | 用于治疗HSP90相关病状的Pochoxime缀合物 |
CA3102782A1 (en) | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
AU2014306867B2 (en) | 2013-08-12 | 2017-10-26 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
ES2845924T3 (es) | 2013-10-15 | 2021-07-28 | Scripps Research Inst | Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos |
CN106536561A (zh) | 2014-05-01 | 2017-03-22 | 豪夫迈·罗氏有限公司 | 抗‑因子d抗体变体及其用途 |
WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
WO2016168773A2 (en) | 2015-04-15 | 2016-10-20 | The California Institute For Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
CN115960230A (zh) | 2015-08-07 | 2023-04-14 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
CN108472382A (zh) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | 抗-因子d抗体变体缀合物及其用途 |
EP3368074A2 (de) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-faktor-d-antikörper und -konjugate |
JP7149935B2 (ja) | 2016-10-19 | 2022-10-07 | ザ スクリプス リサーチ インスティテュート | ヒト化された標的化部分および/または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用 |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
JP7417542B2 (ja) | 2018-01-22 | 2024-01-18 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | Car t細胞の使用方法 |
WO2023179370A1 (en) * | 2022-03-21 | 2023-09-28 | The Hong Kong Polytechnic University | Peptidic bispecific antibody, methods for preparation and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5084398A (en) * | 1987-11-20 | 1992-01-28 | Creative Biomolecules | Selective removal of immune complexes |
-
1993
- 1993-01-08 US US08/002,324 patent/US5861156A/en not_active Expired - Fee Related
-
1994
- 1994-01-07 ES ES94907165T patent/ES2113088T3/es not_active Expired - Lifetime
- 1994-01-07 EP EP94907165A patent/EP0679093B1/de not_active Expired - Lifetime
- 1994-01-07 CA CA002153568A patent/CA2153568A1/en not_active Abandoned
- 1994-01-07 DE DE69406423T patent/DE69406423T2/de not_active Expired - Fee Related
- 1994-01-07 AU AU60846/94A patent/AU673581B2/en not_active Ceased
- 1994-01-07 JP JP6516239A patent/JPH08505623A/ja not_active Ceased
- 1994-01-07 WO PCT/US1994/000261 patent/WO1994015642A1/en active IP Right Grant
- 1994-01-07 AT AT94907165T patent/ATE159429T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU6084694A (en) | 1994-08-15 |
ATE159429T1 (de) | 1997-11-15 |
JPH08505623A (ja) | 1996-06-18 |
WO1994015642A1 (en) | 1994-07-21 |
CA2153568A1 (en) | 1994-07-21 |
US5861156A (en) | 1999-01-19 |
DE69406423D1 (de) | 1997-11-27 |
EP0679093A1 (de) | 1995-11-02 |
ES2113088T3 (es) | 1998-04-16 |
EP0679093B1 (de) | 1997-10-22 |
AU673581B2 (en) | 1996-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE159429T1 (de) | Methode zum überbringen von agenzien an zielzellen | |
NO995044L (no) | Osteoprotegerinbindende proteiner og reseptorer | |
ATE196607T1 (de) | Verfahren zur ex vivo-immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer antikörper | |
NO2012001I2 (no) | Ipilimumab (INN) - krav I basispatent | |
ATE175446T1 (de) | Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung | |
ES2165851T3 (es) | Proteinas multivalentes que se unen a antigenos. | |
DE69129760T2 (de) | T-cadherin-bindungsmolekül | |
ATE387458T1 (de) | Fas-antigenbindender ligand | |
ATE380038T1 (de) | Radiometall-bindende peptide analoge | |
DE69939327D1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
DE68918867D1 (de) | Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen. | |
ATE296312T1 (de) | Metalkomplexbildner | |
DK0572688T3 (da) | Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi | |
DK0920509T3 (da) | Polypeptider, der er i stand til at danne antigenbindende strukturer med specificitet for Rhesus D-antigener, DNA, der koder herfor, samt fremgangsmåde til fremstilling heraf og anvendelse heraf | |
EP0369816A3 (de) | Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper | |
WO2000001820A3 (en) | Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof | |
DE60032143D1 (de) | Verwendung von eif4e-bindungsreagenzien in der therapie | |
ATE407944T1 (de) | Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz | |
AU6839900A (en) | Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence | |
NZ329403A (en) | Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de | ||
8370 | Indication related to discontinuation of the patent is to be deleted | ||
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |